Atlantic Health System’s Morristown Medical Center is the first hospital in New Jersey to offer pediatric patients access to a new clinical study, CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a pediatric population in HCM).
The study evaluates aficamten, a medication designed to reduce the hypercontractility associated with HCM and improve symptoms, in patients with obstructive hypertrophic cardiomyopathy (oHCM).
oHCM is a genetic condition characterized by an overly forceful contraction of the heart muscle (hypercontractility) and an abnormal thickening and stiffening of the left ventricle, the heart’s main pumping chamber. This thickening impairs the heart’s ability to fill adequately with blood and can obstruct blood flow as it exits the heart, forcing the heart muscle to work harder than needed.
“We are incredibly proud to be able to offer our patients access to the CEDAR-HCM clinical trial,” said Matthew W Martinez MD FACC, Director, Sports Cardiology, Director Chanin T. Mast Hypertrophic Cardiomyopathy Center at Morristown Medical Center. “This study represents a significant advancement in the treatment of oHCM in the pediatric population and underscores our commitment to pioneering high-quality health care and research to provide our patients with access to the latest developments in medicine.”
CEDAR-HCM is a multi-center clinical trial evaluating the effectiveness, safety, and pharmacokinetics (PK) of aficamten in the pediatric population with oHCM. The trial is randomized, double-blind, placebo-controlled, and includes an open-label extension.
It will run a total of 78 weeks, and it involves screening, treatment periods, and follow-up phases to evaluate the effects of this next-in-class cardiac myosin inhibitor. The Gagnon Cardiovascular Institute at Morristown Medical Center’s Chanin T. Mast Center for Hypertrophic Cardiomyopathy is the only program in New Jersey.
Morristown Medical Center is the first hospital in New Jersey to offer clinical study of Aficamten to pediatric patients with obstructive hypertrophic cardiomyopathy
bgov.com
July 25, 2024 5:24 pm
Atlantic Health System’s Morristown Medical Center is the first hospital in New Jersey to offer pediatric patients access to a new clinical study, CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a pediatric population in HCM).
The study evaluates aficamten, a medication designed to reduce the hypercontractility associated with HCM and improve symptoms, in patients with obstructive hypertrophic cardiomyopathy (oHCM).
oHCM is a genetic condition characterized by an overly forceful contraction of the heart muscle (hypercontractility) and an abnormal thickening and stiffening of the left ventricle, the heart’s main pumping chamber. This thickening impairs the heart’s ability to fill adequately with blood and can obstruct blood flow as it exits the heart, forcing the heart muscle to work harder than needed.
“We are incredibly proud to be able to offer our patients access to the CEDAR-HCM clinical trial,” said Matthew W Martinez MD FACC, Director, Sports Cardiology, Director Chanin T. Mast Hypertrophic Cardiomyopathy Center at Morristown Medical Center. “This study represents a significant advancement in the treatment of oHCM in the pediatric population and underscores our commitment to pioneering high-quality health care and research to provide our patients with access to the latest developments in medicine.”
CEDAR-HCM is a multi-center clinical trial evaluating the effectiveness, safety, and pharmacokinetics (PK) of aficamten in the pediatric population with oHCM. The trial is randomized, double-blind, placebo-controlled, and includes an open-label extension.
It will run a total of 78 weeks, and it involves screening, treatment periods, and follow-up phases to evaluate the effects of this next-in-class cardiac myosin inhibitor. The Gagnon Cardiovascular Institute at Morristown Medical Center’s Chanin T. Mast Center for Hypertrophic Cardiomyopathy is the only program in New Jersey.